KEYNOTE-024 trial aimed at comparing Pembrolizumab monotherapy vs. platinum-based chemotherapy as first-line therapy for NSCLC patients with PD-L1 expression level ≥ 50% and driver mutations negative. The gene discussed is CD274; the disease is non-small cell lung carcinoma.